Centres d'excellences Laboratoires d'excellence

Immuno-Oncology

ImmunoOnco

Mots-clés : cancer ; chimiothérapie ; immunothérapie ; nutrition ; thérapie ciblée

Résumé

Our Labex has been participating in four major activities, namely, (i) scientific research, (ii) drug development, (iii) biomarker discovery, and (iv) clinical implementation/education. For the sake of brevity only the most spectacular realizations will be mentioned. 

A preliminary assessment of the achievement status of our project leads to the following conclusion: 

-       Our Labex has been a major success, spearheading and accompanying the revolution that has transformed oncology into oncoimmunology. This has been possible due to the capacity of the Labex to harmoniously integrate into a vaster local, French and European ecosystem.

-       Our Labex has contributed to high-level science, drug development, biomarker discovery and educational activities by a variety of instruments including an international scientific organization (EATI), a specialized scientific journal and the creation of spin-off start-ups. 

-       For this reason, the scientific evaluation committee had no specific negative comments on our activity back in 2015. Encouraged by the positive comments of the committee, we extended and expanded our strategy from 2015 until now. That said, we are aware of the necessity to adapt our research network to forthcoming technological and conceptual challenges. 

-       In spite of its relative success, the primary goal of the Labex has not been achieved. Although many immunotherapies delay the physical decline and death of a sizeable fraction of oncological patients, very few individuals with cancer experience definitive cure, and the costs of immuno-oncology drugs (and their failure) are prohibitive for society. The fight must go on. 

 

L'auteur de ce résumé est le coordinateur du projet, qui est responsable du contenu de ce résumé. L'ANR décline par conséquent toute responsabilité quant à son contenu.

Informations générales

Acronyme projet : ImmunoOnco
Référence projet : 10-LABX-0015
Région du projet : Île-de-France
Discipline : 5 - Bio Med
Aide PIA : 16 351 351 €
Début projet : avril 2011
Fin projet : décembre 2024

Coordinateur du projet : Guido KROEMER
Email : kroemer@orange.fr

Consortium du projet

Etablissement coordinateur : Université de Paris
Partenaire(s) : INSERM Délégation Paris 7, Institut Pasteur, INSERM Paris 13, Institut Gustave Roussy, INSERM Délégation Paris 5, INSERM Délégation Paris 6-12, INSERM Délégation Paris 11

Liens utiles